We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Medical

Carocell Bio

Status: Active

Sep 28th 2020 - May 28th 2021

129 days left

Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

read more read less

Carocell Bio Rating Review

Rated on 13/10/2020

Pitch Rated

45%

Insufficient Data

Management

77%

Product

58%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Pitch rating powered by CROWDRATING

  • Withheld
    pledged

    £720,000
    target

    £4,058,252
    pre-money valuation

    20.00%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    10469714
    company number

    Active
    company status

    08/11/2016
    incorporated 4 years

    £0.04
    share price

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating
Click here for more information on our ratings
Login to view the full report

Management 77%

Skills 73%
Carocell Bio’s Management team is led by the Founder/CEO, who has expertise in early-stage development and taking medicines from ideation to the market. He is skilled in clinical development, drug discovery, clinical research, medical education, drug development, pharmacology, and regulatory submissions. The Chairman is an expert in clinical development, biotechnology, cell culture, new business development, strategic leadership, technology transfer, and toxicology. The Marketing Director is well versed in brand development, marketing management, business administration, SEO copywriting, strategic planning, production management, online advertising, and marketing communications. It was noted that they have not, as yet, appointed a dedicated Finance Head and CEO is also taking up the responsibilities of Product Developer in the team.

0 comments

Log in to comment


Funding progress

not enough data

More from Medical

FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
pledged: 160% days to go: 23 investment: £482,450

  • Withheld
    pledged

    £720,000
    target

    £4,058,252
    pre-money valuation

    20.00%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    10469714
    company number

    Active
    company status

    08/11/2016
    incorporated 4 years

    £0.04
    share price

  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph